🇺🇸 Zidovudine (ZDV) in United States

14 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 28 March 2025 – 28 March 2026
• Total reports: 14

Most-reported reactions

1. Virologic Failure — 5 reports (35.71%)
2. Anaemia — 1 report (7.14%)
3. Anorexia — 1 report (7.14%)
4. Bacteriuria — 1 report (7.14%)
5. Creatinine Renal Clearance Decreased — 1 report (7.14%)
6. Decreased Activity — 1 report (7.14%)
7. Dehydration — 1 report (7.14%)
8. Electrolyte Imbalance — 1 report (7.14%)
9. Haemolysis — 1 report (7.14%)
10. Hepatitis Acute — 1 report (7.14%)

Source database →

Frequently asked questions

Is Zidovudine (ZDV) approved in United States?

Zidovudine (ZDV) does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Zidovudine (ZDV) in United States?

National Institute of Allergy and Infectious Diseases (NIAID) is the originator. The local marketing authorisation holder may differ — check the official source linked above.